Proteasome inhibitor, bortezomib, for myeloma and lymphoma

被引:0
|
作者
Kensei Tobinai
机构
[1] National Cancer Center Hospital,Hematology and Stem Cell Transplantation Division
关键词
Proteasome inhibitor; Bortezomib; Multiple myeloma; Lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
Bortezomib, a boronic acid, is a potent and selective proteasome inhibitor. The 20S proteasome is an enzyme complex present in cells, and it degrades many cell-cycle control factors, signal transduction factors, transcription factors, and oncogene and anti-oncogene products, thus controlling cell proliferation, differentiation, and apoptosis. Bortezomib is a novel molecular targeting agent which was designed to exhibit an antitumor effect by selectively inhibiting the 20S proteasome. Multiple myeloma is one of the incurable B-cell malignancies that continues to relapse with current treatment modalities, and the duration to progression becomes shorter in patients who repeatedly receive chemotherapy. There are no available treatment options in which durable efficacy can be expected after relapse; therefore, an effective therapy with a novel mechanism of action has been desired. In this review article, the results of clinical trials of bortezomib for multiple myeloma, including a Japanese phase I/II and pharmacokinetic/pharmacodynamic study, and those for non-Hodgkin lymphoma, especially for mantle cell lymphoma, are summarized. In the Japanese phase I/II study of bortezomib for relapsed multiple myeloma, this agent showed remarkable efficacy, with acceptable toxicities and unique pharmacokinetic/pharmacodynamic profiles, warranting further investigations, including more relevant administration schedules.
引用
收藏
页码:318 / 326
页数:8
相关论文
共 50 条
  • [1] Proteasome inhibitor, bortezomib, for myeloma and lymphoma
    Tobinai, Kensei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 318 - 326
  • [2] A review of the proteasome inhibitor bortezomib in multiple myeloma
    Richardson, PG
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) : 1321 - 1331
  • [3] Proteasome inhibitor bortezomib for the treatment of multiple myeloma
    Cavo, M.
    [J]. LEUKEMIA, 2006, 20 (08) : 1341 - 1352
  • [4] Proteasome inhibitor bortezomib for the treatment of multiple myeloma
    M Cavo
    [J]. Leukemia, 2006, 20 : 1341 - 1352
  • [5] Bortezomib - first proteasome inhibitor for the treatment of multiple Myeloma
    Jurczyszyn, Artur
    Skotnicki, Aleksander B.
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2007, 11 (03): : 112 - 124
  • [6] The combination of the MTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma
    Leleu, X.
    O'Sullivan, G.
    Jia, X.
    Ngo, H.
    Moreau, A. S.
    Roccaro, A.
    Hatjiharisi, F.
    Hideshima, T.
    Anderson, K.
    Ghobrial, I.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 148 - 149
  • [7] Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
    Hacihanefioglu, Abdullah
    Tarkun, Pinar
    Gonullu, Emel
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) : 219 - 222
  • [8] Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma
    Malissen, Nausicaa
    Bourrain, Jean-Luc
    Chiriac, Anca
    Montet, Aline
    Vincent, Laure
    Dereure, Olivier
    Du-Thanh, Aurelie
    [J]. ACTA DERMATO-VENEREOLOGICA, 2016, 96 (07) : 995 - 996
  • [9] Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
    Abdullah Hacihanefioglu
    Pinar Tarkun
    Emel Gonullu
    [J]. International Journal of Hematology, 2008, 88 : 219 - 222
  • [10] The proteasome inhibitor bortezomib overcomes the inhibition of osteoblast function observed in multiple myeloma
    Lund, T.
    Soe, K.
    Abilgaard, N.
    Garnero, P.
    Pedersen, P. T.
    Ormstrup, T. E. J.
    Delaisse, J.
    Plesner, T.
    [J]. BONE, 2010, 47 : S304 - S305